Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Ridgeback Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Emory's DRIVE, Ridgeback partnering for drug vs coronavirus
Details : Ridgeback has exclusively licensed DRIVE's EIDD-2801 and will be responsible for advancing it through clinical development and ensuring that EIDD-2801 is available during current pandemic.
Product Name : EIDD-2801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Ridgeback Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nonprofit drug development company starts GoFundMe for emergency funds to treat coronavirus
Details : DRIVE is developing the compound, designated EIDD-2801, which has shown efficacy against other coronaviruses such as SARS-CoV and MERS-CoV.
Product Name : EIDD-2801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable